Department of Orthopedic Surgery, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.
Knee Surg Sports Traumatol Arthrosc. 2011 Feb;19(2):277-84. doi: 10.1007/s00167-010-1213-2. Epub 2010 Jul 17.
in the last decade, a major increase in the use of and interest in unicompartmental knee arthroplasty (UKA) has developed. The Oxford Phase 3 UKA is implanted with a minimally invasive technique using newly developed instruments. The objective of this prospective study was to evaluate the outcome of UKA in patients with medial osteoarthritis of the knee in a high-volume unit.
two-hundred and forty-four UKAs were performed with a minimally invasive approach. The median age was 72 (43-91) years. The median follow-up was 4.2 years (range 1-10.4 years). Fourteen patients died, and nine were considered to be lost to follow-up, but all had a well-functioning prosthesis in situ until their last follow-up. Pain, function and health-related quality of life were evaluated pre- and postoperatively using patient- and assessor-based outcome scores, as well as radiographic evidence.
the mean Knee Society knee and function scores, WOMAC-scores, Oxford-score and VAS pain and satisfaction all improved. Nine knees required revision. Eleven patients required an additional arthroscopic procedure due to persisting pain secondary to intra-articular pathology, and four patients required manipulation under anaesthesia because of limited range of motion. The 7-year cumulative survival rate of the arthroplasty was 94.4%. A low incidence (21%) of a radiolucent line beneath the tibial component was observed at 5 years of follow-up.
this study showed a high survival rate of the Oxford Phase 3 UKA. Patient satisfaction and functional performance were also very high. Major complication rate was low; in addition, the incidence of radiolucency under the tibial component, when compared to present literature, was low. When strict indication criteria are followed, excellent, durable, and in our opinion reliable, results can be expected for this procedure.
在过去十年中，单髁膝关节置换术（UKA）的应用和关注度有了显著增加。牛津 Phase 3 UKA 采用微创技术，使用新开发的器械进行植入。本前瞻性研究的目的是评估在高容量单位中，膝关节内侧骨关节炎患者接受 UKA 的结果。
采用微创方法进行了 244 例 UKA。中位年龄为 72 岁（43-91 岁）。中位随访时间为 4.2 年（范围 1-10.4 年）。14 例患者死亡，9 例被认为随访丢失，但所有患者在最后一次随访时均有功能良好的假体在位。使用患者和评估者为基础的结局评分以及影像学证据，评估术前和术后的疼痛、功能和健康相关生活质量。
膝关节学会膝关节和功能评分、WOMAC 评分、牛津评分和 VAS 疼痛评分及满意度均有所改善。9 例膝关节需要翻修。11 例患者因关节内病变导致持续性疼痛需要进行额外的关节镜手术，4 例患者因活动范围受限需要在麻醉下进行手法复位。关节置换的 7 年累积生存率为 94.4%。在 5 年随访时，观察到胫骨组件下低发生率（21%）的透亮线。
本研究显示牛津 Phase 3 UKA 的生存率较高。患者满意度和功能表现也非常高。主要并发症发生率较低；此外，与现有文献相比，胫骨组件下的透亮率较低。当遵循严格的适应证标准时，该手术可获得出色、持久且在我们看来可靠的结果。
